ABL1 and leukemia: Thus, while the median survival of mice with leukemia driven by BCR-ABL/MSI2-HOXA9ΔHOXA9 (BCR-ABL/ΔHOXA9) was 26 days, the loss of RRM1 led to a median survival of 46 days, similar to BCR-ABL alone (43.5 days).